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Hepatic epithelioid hemangioendothelioma is a rare livermesenchy-
matous tumor with an epithelial aspect developed from endothelial
cells with a lack of validated therapeutic options at metastatic stage.
Metronomic chemotherapyhasbeendescribedas ananti-angiogenic
therapy leading to the depletion of circulating endothelial progeni-
tors. We report the results of two patients treated for metastatic
hemangioendothelioma with metronomic cyclophosphamide che-
motherapy. Following initiation of metronomic cyclophosphamide
chemotherapy (50 mg once a day continuously), the two patients
exhibited signiﬁcant clinical improvement and decrease in metasta-
sis sizewithoutanyclinically relevant side-effect.Metronomic cyclo-
phosphamide could be proposed as a new therapeutic option to
treat metastatic hepatic epithelioid hemangioendothelioma.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
First described in 1982 by Weiss and Enzinger, hepatic epitheli-
oid hemangioendothelioma (HEH) is a rare mesenchymatous
tumor with low to intermediate grade of malignancy and may
often be confused with other solitary ﬁbrous tumors such as
angiosarcoma [1]. In almost half of the cases, HEH is revealed
at metastatic stage with preferential pulmonary and bone locali-
zation [2]. Surgery with partial hepatectomy or liver transplanta-
tion is the ﬁrst-line treatment when HEH is conﬁned to the liver.
Other treatments have been reported such as chemotherapy,
radiotherapy, hormonotherapy, and embolization. Low doses of
metronomic chemotherapy have been shown to inhibit endothe-Journal of Hepatology 20
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[3]. Since HEH is characterized by a proliferation of endothelial
cells exhibiting an epithelioid phenotype, we hypothesized that
cyclophosphamide-based metronomic chemotherapy (CMC)
could be an effective treatment. We report here two cases of
patients with metastatic HEH treated by CMC at dose of 50 mg
a day without interruption.Case reports
We report the case of a 58-year-old woman who was referred to
the university hospital for a grade III dyspnea appeared in early
2006. HEH was diagnosed using a transbronchial biopsy of sec-
ondary lesions. A CT scan also identiﬁed splenic and liver metas-
tases. A ﬁrst-line chemotherapy by bevacizumab was initiated
with progression of the disease observed after only 3 months.
Then 3 cycles of adriamycin regimen were administrated and dis-
continued because of clinical toxicity. After an exhaustive multi-
disciplinary discussion, CMC was introduced in July 2006. The
rationale for the use of CMC was based on its known anti-angio-
genic property, physiopathology of HEH with proliferation of
endothelial cells, and no possibility to access novel targeted
anti-angiogenic agents at that time. A radiological objective
response was conﬁrmed on CT scan. The complete response of
the liver lesion identiﬁed by CT scan sustains the bioactivity of
metronomic cyclophosphamide in this patient (Fig. 1). The clini-
cal beneﬁt of this strategy was also suggested by the relief of
pain, dyspnea and anaemia. Of note, no toxicity was reported
during the exposition to metronomic cyclophosphamide. Because
of clinical progression of dyspnea, CMC therapy was interrupted
in December 2006. During the following 6 months, three lines
of chemotherapy were initiated including weekly paclitaxel,
HELP protocol (etoposide, ifosfamide and cisplatin), and suniti-
nib. None of these treatments provided any clinical or radiologi-
cal efﬁcacy. Patient’s death occurred in May 2007 after initiation
of best supportive cares.
The second case report is about a 40-year-old man who
underwent routine examinations in 1996 during the follow-up
of occupational medicine, and HEH with lung metastasis was
fortuitously diagnosed and conﬁrmed by hepatic biopsy.
A disease staging was performed and a simple monitoring was13 vol. 58 j 1254–1257
Fig. 2. Treatment of a 40-year-old man bearing a metastatic HEH with metronomic cyclophosphamide. A symptomatic lung inﬁltrate of metastatic HEH was
diagnosed. (A) The clinical efﬁcacy of metronomic cyclophosphamide was suggested by the disappearance of lung micro-metastases. (B) A liver lesion was also diagnosed
and displayed a long-term stable disease.
Fig. 1. A 58-year-old woman with HEH was treated with metronomic cyclophosphamide. The best response was observed in a liver metastasis located in the right liver.
This liver lesion was measured at baseline with a maximum diameter of 20 mm (white arrowheads). A radiological response was observed following two months of CMC
and the lesion totally disappeared thereafter.
JOURNAL OF HEPATOLOGYinitiated because of the absence of symptoms. Four years later,
symptomatic bone metastases appeared and were treated by
sodium pamidronate every 4 weeks. The patient remained
under simple surveillance until lung and liver progression in
May 2008. Based on the former experience, CMC was initiated
in July 2008 at the daily dose of 50 mg. Clinical and radiolog-
ical responses were observed with decrease of the size of
lesions at CT exams as well as complete pain relief with dis-
continuation of opioid drugs (Fig. 2). Treatment by CMC was
maintained almost 2 years until May 2010 and was stopped
at this date because of a haematological toxicity characterized
by pancytopenia. Second-line treatment by etoposide was per-
formed from December 2010 to April 2011 without efﬁcacy,
but clinical and biological toxicity. Best supportive cares were
then started.Journal of Hepatology 2013Discussion
Hepatic epithelioid hemangioendothelioma is a rare mesenchy-
matous tumor with an epithelial aspect developed from endothe-
lial cells. From 1984 to 2006, 434 cases of HEH have been
reported with only 252 cases of liver primitive disease [4]. HEH
has a low to intermediate grade of malignancy between liver hae-
mangioma and angiosarcoma, but its evolution is unpredictable.
HEH generally affects middle-aged adults predominantly
women. Initial symptoms are usually abdominal pain rather in
the right upper quadrant, with sometimes weight loss, but no
alteration of performance status. Clinical examination may reveal
hepatomegaly but is often poor. Biological tests are most of the
time normal and may only reveal perturbation of liver enzymes.
Tumor markers are always normal. Radiological tools may bevol. 58 j 1254–1257 1255
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helpful for diagnosis. Ultrasonography shows hepatic nodules
either homogeneously hypoechogenic or centered by a hypere-
chogenic structure with a peripheral hypoechogenic structure.
CT and MRI may reveal a ‘halo’ sign due to central coagulative
necrosis and a ‘capsular retraction’ sign caused by an intense
ﬁbroproliferation [5]. A ‘lollypop’ sign has also been described
as a sign of HEH [6]. Some authors also reported FDG-PET/CT as
a contributive exam in HEH diagnosis and staging [7]. The deﬁn-
itive diagnosis of HEH is conﬁrmed by histopathological analysis
and immunohistochemistry with positive staining for FVIII-Rag,
CD31, CD34 and Ulex europaeus 1 [8].
Treatment of localized HEH requires surgery with partial or
total hepatectomy. Many authors reported a beneﬁt on survival
after liver resection [9]. Liver transplantation is another thera-
peutic option [10].
In metastatic HEH or non-operable patients, many regimens
of chemotherapy have been tried without any evidence for a
ﬁrst-line treatment due to low incidence of HEH. The endothe-
lial-related proliferation observed in HEH sustains the rationale
for anti-angiogenic therapies in this disease [11]. Thus, thalid-
omide showed a signiﬁcant and clinical effect on HEH in some
studies due to properties of neo-angiogenesis inhibition [12].
Some efﬁcacy was also reported for interferon-alpha in isolated
cases of HEH and some authors evoked its anti-anti-angiogenic
properties [13–17]. Of note, other anti-angiogenic targeted
agents, such as sorafenib and bevacizumab, showed clinical
beneﬁt in isolated case reports of HEH from different sites
[18–20]. Sorafenib led to a long-term tumor stabilization in a
patient treated for HEH with lung and liver metastases [18].
Moreover, while our patients did not beneﬁt from bevacizumab
therapy, other reports have shown stabilization of HEH metas-
tases and long-term disease control following bevacizumab ini-
tiation [19,20].
CMC consists of daily and continuous administration of cyclo-
phosphamide at low concentration. Multifactorial modes of
action, including immunological and anti-angiogenic functions,
were described. Low doses of cyclophosphamide are able to
enhance immune response against a variety of antigens. In the
murine model, metronomic cyclophosphamide has shown a
decreased activity of regulatory T cells (TREGs) implicated in toler-
ance to self-antigens, such as tumour-associated antigens [21].
Furthermore, CMC decreases the level of immunosuppressive
cytokines, such as TGF-b, IL-10, and IL-2, and stimulates the
recovery of IFN-gamma-producing natural killer T cells, and the
maturation of dendritic cells, maintains the survival of memory
T cells, and stimulates Galactin-1 expression in primary tumor,
metastasis, and spleen cells [22]. Several studies demonstrated
anti-angiogenic properties of CMC. Endothelial cells required in
the neo-angiogenic process are susceptible to cytotoxicity
induced by chemotherapy as any other dividing cells. It is now
well established that under metronomic regimen, endothelial cell
sub-lethal or lethal alterations are observed, and continuous
exposure may deﬁnitively compromise their recovery [22–24].
In contrast to the high dose of cyclophosphamide, which induces
mobilization of circulating endothelial cells, a few days after the
end of a cycle of drug administration, CMC produces a long-last-
ing effect in endothelial and their circulating progenitor cells,
inducing more durable tumor growth inhibition [25]. The anti-
angiogenic property of CMC regimen is also suggested by the
overexpression of thrombospontin-1, an anti-angiogenic factor,
in patients treated with this strategy [26,27].1256 Journal of Hepatology 2013CMC regimen was already used in prospective phase II trials
for several cancer types, mostly in advanced breast and prostate
cancers [22]. In breast cancer, clinical beneﬁt of CMC in combina-
tion with low dose methotrexate was demonstrated in several
prospective phase II trials [28,29]. As second-line treatment in
metastatic setting, the disease control rate was 31.7%, compara-
ble to other second-line regimens [30]. Cost/effective analysis
also favoured this regimen [31]. In prostate cancer, two prospec-
tive phase II studies evaluated CMC regimen as monotherapy in
castration-refractory prostate cancer (CRPC). Raghavan et al. eval-
uated 30 patients with measurable disease. Disease control was
observed in 18 out of 30 patients, and median OS was
12.7 months. Lord et al. reported 80 CRPC patients treated by
metronomic chemotherapy after failure of conventional chemo-
therapies. Overall response rate was 34.5%, and PFS was
7.5 months. The treatment was well tolerated. The only grade
III-IV toxicities were haematological, mostly lymphopenia
[32,33].
Based on these ﬁndings, we hypothesized that CMC could be
an attractive therapy to treat a vascular tumor as HEH. Of note,
in the two case reports described here, lung micro-metastases
were associated with liver lesions. In both cases, the initiation
of CMC was decided because of symptoms such as dyspnea or
pain. Our multidisciplinary team validated CMC in this orphan
disease lacking a validated systemic treatment in advanced stage.
In both cases, CMC induced a relief of symptoms with accept-
able tolerance and easily manageable and reversible toxicities.
Moreover, CMC was able to induce a partial radiological response,
in line with a potential clinical interest of CMC in the disease. The
efﬁcacy of CMC is emphasized by the complete disappearance of
the liver disease in patient 1 and of most lung micro-metastases
in patient 2. Of note, in the two case reports described here, CMC
was the only chemotherapy able to provide a clinical beneﬁt or a
radiological objective response. These results are also supported
by another observation reported in 2011. This study assessed
the clinical interest of metronomic cyclophosphamide delivering
100 mg of cyclophosphamide twice daily plus 20 mg of prednis-
olone the ﬁrst week of a two-week cycle, in 26 advanced or met-
astatic soft tissue sarcoma, including one metastatic HEH [34].
CMC was associated with a 26.9% response rate. A complete
response of the liver metastases of the HEH patient was observed.
Altogether, these reports conﬁrm the efﬁcacy of CMC in this rare
disease.
HEH is a rare disease with low incidence that does not allow a
comparative study between two regimens of chemotherapy.
Because of clinical efﬁcacy, good acceptance, low toxicity and
low cost, CMC could be proposed as a new palliative therapeutic
option to treat metastatic or non-operable HEH.Conﬂict of interest
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